Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Representative before the EPO

Technology company logo thumb
no operation time available
1 office
Technology Company

Nicholas James Finnie has worked on the following 7 EPO patent applications which have been published in the last five years:

EP11716449

METHOD FOR GENERATING A PARVOVIRUS B19 VIRUS-LIKE PARTICLE

IPC classification:
C07K 14/015, C12N 7/04
Applicant:
Novartis AG
Agent:
Cameron John Marshall, Carpmaels & Ransford LLP
Agent:
Nicholas James Finnie, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP12709383

METHOD FOR DETECTING PARVOVIRUS ANTIGEN

IPC classification:
G01N 33/569
Applicant:
University of Regensburg (Universit├Ąt Regensburg)
Applicant:
Novartis AG
Agent:
Carpmaels & Ransford LLP
Agent:
Nicholas James Finnie, Novartis Pharma AG
Status:
APPLICATION DEEMED TO BE WITHDRAWN
EP14160481

Alphavirus vectors for RSV and PIV vaccines

IPC classification:
A61K 39/00, A61K 39/02, A61K 39/12, A61K 39/145, A61K 39/155, A61K 39/215, A61K 39/295, C12N 15/86
Applicant:
Novartis Vaccines and Diagnostics Inc.
Agent:
Cameron John Marshall, Carpmaels & Ransford LLP
Agent:
Nicholas James Finnie, Novartis Pharma AG
Status:
EXAMINATION IN PROGRESS
EP14189933

Alphavirus vectors for influenza virus vaccines

IPC classification:
A61K 39/00, A61K 39/02, A61K 39/12, A61K 39/145, A61K 39/155, A61K 39/215, A61K 39/295, C12N 15/86
Applicant:
Novartis Vaccines and Diagnostics Inc.
Agent:
Cameron John Marshall, Carpmaels & Ransford LLP
Agent:
Nicholas James Finnie, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14700356

INFLUENZA VIRUS IMMUNOGENIC COMPOSITIONS AND USES THEREOF

IPC classification:
A61K 39/145, C12N 7/04, C12N 15/867
Applicant:
Novartis AG
Agent:
Carpmaels & Ransford LLP
Agent:
Nicholas James Finnie, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14736835

ROTAVIRUS PARTICLES WITH CHIMERIC SURFACE PROTEINS

IPC classification:
C07K 14/14
Applicant:
Novartis AG
Applicant:
Children's Medical Center Corporation
Applicant:
Brandeis University
Agent:
Nicholas James Finnie, Novartis Pharma AG
Status:
GRANT OF PATENT INTENDED
EP14798760

REMOVAL OF RESIDUAL CELL CULTURE IMPURITIES

IPC classification:
A61K 39/00, C07K 1/18
Applicant:
Novartis AG
Agent:
Florian Bielefeldt, Novartis AG
Agent:
Nicholas James Finnie, Novartis International AG
Status:
EXAMINATION REQUESTED

Please Sign in to use this feature